Alvotech’s Ustekinumab Passes Safety And Efficacy Milestone
Company Reports Fresh Data For AVT04 Biosimilar Rival To Stelara
Executive Summary
Alvotech has announced success in its confirmatory clinical safety and efficacy study for its AVT04 ustekinumab candidate, a proposed biosimilar to Stelara.
You may also be interested in...
Alvotech Kicks Off Trials For Eylea Biosimilar
Alvotech has announced the start of clinical trials for its AVT06 proposed aflibercept biosimilar rival to Eylea, joining a host of other developers pursuing the same target.
Icelandic Exchange Approves Alvotech As Its Shares Trade In NY
Alvotech is celebrating an “historic milestone” as it became a publicly listed company in New York, with its shares set to also trade in its domestic Iceland next week.
Stada And Alvotech Launch Higher-Strength Adalimumab In Europe
Stada and Alvotech have announced the launch of the Hukyndra higher-strength adalimumab biosimilar rival to Humira in selected European countries, with a wider roll-out to follow in the coming months.